PEPGEN INC. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
PEPGEN INC. (PEPG) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent of -1.70% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch · last filed 2026-03-04
- PEPGEN INC. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2025 was -1.70%.
- PEPGEN INC. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2024 was -3.40%.
- PEPGEN INC. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2023 was -3.20%, a 300.00% decline from fiscal 2022.
- PEPGEN INC. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2022 was 1.60%, a 700.00% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -1.70% 10-K · filed 2026-03-04 | |
| 2024-12-31 | -3.40% 10-K · filed 2026-03-04 | |
| 2023-12-31 | -3.20% 10-K · filed 2025-02-24 | 3.20% 10-K · filed 2024-03-06 |
| 2022-12-31 | 1.60% 10-K/A · filed 2024-03-29 | |
| 2021-12-31 | 0.20% 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |